ANDA 218878, held by Baxter Hlthcare Corp. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 218878 (Succinylcholine Chloride), held by Baxter Hlthcare Corp, was first approved by FDA on Sep 24, 2024, with 0 approved supplements and 0 published complete response letters.
Succinylcholine chloride injection is indicated in adults and pediatric patients:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters